| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SDH |
| Uniprot No | P20132 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-328aa |
| 氨基酸序列 | MMSGEPLHVKTPIRDSMALSKMAGTSVYLKMDSAQPSGSFKIRGIGHFCKRWAKQGCAHFVCSSAGNAGMAAAYAARQLGVPATIVVPSTTPALTIERLKNEGATVKVVGELLDEAFELAKALAKNNPGWVYIPPFDDPLIWEGHASIVKELKETLWEKPGAIALSVGGGGLLCGVVQGLQEVGWGDVPVIAMETFGAHSFHAATTAGKLVSLPKITSVAKALGVKTVGAQALKLFQEHPIFSEVISDQEAVAAIEKFVDDEKILVEPACGAALAAVYSHVIQKLQLEGNLRTPLPSLVVIVCGGSNISLAQLRALKEQLGMTNRLPK |
| 预测分子量 | 42.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SDH(琥珀酸脱氢酶)重组蛋白的参考文献示例(注：以下内容为虚构，仅供格式参考)：
---
1. **文献名称**：*"Heterologous Expression and Purification of Functional Succinate Dehydrogenase in Saccharomyces cerevisiae"*
**作者**：Zhang, Y. et al.
**摘要**：研究通过酵母表达系统成功重组表达了具有酶活性的SDH复合体，优化了纯化流程，并验证其在三羧酸循环中的催化功能，为遗传性SDH缺陷疾病模型提供了工具。
2. **文献名称**：*"Structural and Functional Analysis of Pathogenic SDHB Mutants Using Recombinant Protein Technology"*
**作者**：Garcia, R. et al.
**摘要**：利用大肠杆菌重组表达携带致癌突变的SDHB亚基，发现突变导致SDH复合体稳定性下降和线粒体活性氧积累，揭示了SDH缺陷与肿瘤发生的关系。
3. **文献名称**：*"High-Yield Production of Recombinant SDH Complex in Insect Cells for Drug Screening Applications"*
**作者**：Wang, L. et al.
**摘要**：采用昆虫细胞-杆状病毒系统高效表达全酶SDH复合体，开发了基于重组蛋白的抑制剂筛选平台，用于靶向代谢疾病的药物发现。
4. **文献名称**：*"Role of SDHAF2 in the Assembly of Recombinant SDH: Insights from in vitro Reconstitution"*
**作者**：Kim, S. et al.
**摘要**：通过体外重组实验证明SDHAF2伴侣蛋白对SDH亚基的正确组装至关重要，并阐明了其分子机制。
---
(注：以上文献为示例，实际研究中请通过学术数据库检索真实文献。)
**Background of SDH Recombinant Proteins**
Succinate dehydrogenase (SDH), also known as mitochondrial Complex II, is a critical enzyme located in the inner mitochondrial membrane. It serves a dual role in both the tricarboxylic acid (TCA) cycle, where it catalyzes the oxidation of succinate to fumarate, and the electron transport chain (ETC), transferring electrons to ubiquinone. Structurally, SDH is a heterotetramer composed of four subunits (SDHA, SDHB, SDHC, SDHD), with SDHA/SDHB forming the catalytic core and SDHC/SDHD anchoring the complex to the membrane.
Mutations in SDH subunits or assembly factors are linked to severe metabolic disorders, including hereditary paragangliomas, pheochromocytomas, and Leigh syndrome, as well as mitochondrial diseases. These dysfunctions disrupt cellular energy metabolism, promote oxidative stress, and alter succinate-mediated signaling pathways, contributing to tumorigenesis and neurodegeneration.
Recombinant SDH proteins are engineered to study these mechanisms and develop therapeutic strategies. Produced via heterologous expression systems (e.g., *E. coli*, yeast, or mammalian cells*), they enable structural analysis, functional assays, and drug screening. Challenges include preserving enzymatic activity, proper folding, and incorporation of essential cofactors (e.g., FAD, iron-sulfur clusters). Advances in protein engineering and cryo-EM have improved SDH complex reconstitution, aiding in the study of disease-associated variants.
SDH recombinant proteins also hold potential for enzyme replacement therapies and as biomarkers. However, their clinical application requires overcoming delivery challenges to mitochondria and ensuring stability *in vivo*. Overall, SDH recombinant tools are vital for unraveling mitochondrial biology and translating findings into targeted treatments for SDH-related pathologies.
*(Word count: 247)*
×
